A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003 in Patients With Solid Cancer

Chunhoo Cheon, Seong-Gyu Ko, Chunhoo Cheon, Seong-Gyu Ko

Abstract

Background: Cancer is a major health problem worldwide and the leading cause of death in many countries. Preclinical studies have shown the therapeutic anticancer effects of SH003, a novel herbal medicine containing Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii. The present study investigated the maximum tolerated dose of SH003 in patients with solid cancers. Methods: This open-label, dose-escalation trial used the traditional 3 + 3 dose-escalation design. Patients with solid cancers were recruited and administered 1 to 4 tablets of SH003 thrice daily for 3 weeks according to the dose level. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). Dose-limiting toxicities (DLTs) were defined as Grade 3 or higher adverse events based on CTCAE. The maximum tolerated dose was defined as the highest dose at which no more than 1 of 6 patients experienced DLT. Results: The present study enrolled 11 patients. A total of 31 adverse events occurred. According to the CTCAE, all the observed adverse events were grade 2 or less and no adverse events of grade 3 or more corresponding to DLT occurred. Conclusion: The study results indicated that the maximum tolerated dose of SH003 was 4800 mg/day. A Phase 2 study is required to determine the efficacy of SH003 in patients with cancer at a dose of 4800 mg/day or less.

Trial registration: ClinicalTrials.gov NCT03081819.

Keywords: SH003; cancer; first-in-human; herbal medicine; maximum tolerated dose; phase 1; safety.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Participant flowchart. Abbreviation: DLT, dose-limiting toxicity.

References

    1. World Health Organization. Fact sheets: cancer. . Accessed February 21, 2020.
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
    1. National Cancer Information Center. National Cancer Center [in Korean]. . Accessed September 11, 2019.
    1. Hyun KR, Lee SM. Analysis of socioeconomic costs of five major diseases. Health Insur Policy. 2014;13:91-107.
    1. Hyun KR, Choi KC, Lee SM, Lee SY. Analysis of Socioeconomic Costs of Major Diseases for Establishment of Health Policy. Wonju, South Korea: National Health Insurance Service; 2017.
    1. Yin SY, Wei WC, Jian FY, Yang NS. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med. 2013;2013:302426.
    1. Peltzer K, Pengpid S. The use of herbal medicines among chronic disease patients in Thailand: a cross-sectional survey. J Multidiscip Healthc. 2019;12:573-582.
    1. Auyeung KK, Han QB, Ko JK. Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers. Am J Chin Med. 2016;44:1-22.
    1. Choi HS, Cho SG, Kim MK, et al. Decursin in Angelica gigas Nakai (AGN) enhances doxorubicin chemosensitivity in NCI/ADR-RES ovarian cancer cells via inhibition of P-glycoprotein expression. Phytother Res. 2016;30:2020-2026.
    1. Li J, Li H, Zhang Z, Wang N, Zhang Y. The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3. Biol Res. 2016;49:21.
    1. Choi YK, Cho SG, Choi YJ, et al. SH003 suppresses breast cancer growth by accumulating p62 in autolysosomes. Oncotarget. 2016;8:88386-88400.
    1. Choi YK, Cho SG, Woo SM, et al. Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediators Inflamm. 2014;2014:492173.
    1. Choi HS, Kim MK, Lee K, et al. SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2. Oncotarget. 2016;7:32969-32979.
    1. Choi YJ, Choi YK, Lee KM, Cho SG, Kang SY, Ko SG. SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway. BMC Complement Altern Med. 2016;16:507.
    1. Lee KM, Lee K, Choi YK, Choi YJ, Seo HS, Ko SG. SH003induced G1 phase cell cycle arrest induces apoptosis in HeLa cervical cancer cells. Mol Med Rep. 2017;16:8237-8244.
    1. National College of Korean Medicine Publication Committee on Joint Textbook. Herbology. Seoul, Korea: Younglimsa; 2016.
    1. Cheon C, Kang S, Ko Y, et al. Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol. BMJ Open. 2018;8:e019502.
    1. National Institute of Food and Drug Safety Evaluation. The Korean herbal pharmacopoeia [in Korean]. . Accessed January 16, 2020.
    1. Storer BE. An evaluation of phase I clinical trial designs in the continuous dose-response setting. Stat Med. 2001;20:2399-2408.
    1. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. . Accessed February 22, 2020.
    1. National Development Institute of Korean Medicine. Report of Korean Medicine Utilization Survey—General Population, 2017. Seoul, Korea: National Development Institute of Korean Medicine; 2018.
    1. Wu YC, Hsieh CL. Pharmacological effects of Radix Angelica sinensis (Danggui) on cerebral infarction. Chin Med. 2011;6:32.
    1. Woo SM, Kim AJ, Choi YK, Shin YC, Cho SG, Ko SG. Synergistic effect of SH003 and doxorubicin in triple-negative breast cancer. Phytother Res. 2016;30:1817-1823.
    1. Choi HS, Cho SG, Kim MK, et al. SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity. Mol Cell Biochem. 2017;426:1-8.
    1. Gang JS. Establishment of Marker Compounds and Content Criteria for Herbal Medicines [in Korean]. Osong, Korea: Ministry of Food and Drug Safety; 2014.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅